Premium
CHRONIC DIPHENYLHYDANTOIN THERAPY DOES NOT REDUCE PLASMA 25‐HYDROXY‐VITAMIN D
Author(s) -
WARK J. D.,
LARKINS R. G.,
PERRYKEENE D.,
PETER C. T.,
ROSS D. L.,
SLOMAN J. G.
Publication year - 1979
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1979.tb03074.x
Subject(s) - medicine , endocrinology , alkaline phosphatase , plasma levels , vitamin d and neurology , plasma concentration , chemistry , enzyme , biochemistry
SUMMARY A randomized controlled study was performed to investigate the effect of 2 years’monitored diphenylhydantoin (DPH) therapy on plasma 25‐hydroxyvitamin D (25‐OHD) in nonepileptic, non‐institutionalized subjects. Mean ± SEM plasma 25‐OHD of 18 DPH‐treated subjects at the end of 2 years’drug treatment was 59 ± 8 nmol/l (23.6 ± 3.2 ng/ml), which was not decreased compared to that of eighteen control subjects (54±8 nmol/l, 21.6±3.2 ng/ml). In addition, mean plasma 25‐OHD had not changed 1 month after ceasing DPH. The treated group had a higher mean serum alkaline phosphatase (SAP) during DPH treatment, attributable to hepatic enzyme induction. It is concluded that therapeutic doses of DPH without other anticonvulsants do not have a clinically significant effect on plasma 25‐OHD.